Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of JNJ-77242113 vs Placebo and Deucravacitinib in Moderate to Severe Plaque Psoriasis
jRCT2031230594Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in plaque psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: IGA 0 or 1 with ≥2-grade improvement at Week 16 (JNJ-77242113 vs placebo) and PASI 90 response at Week 16 (JNJ-77242113 vs placebo). Started Mar 2024; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2031230594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230594.